Maturitas
Volume 55, Issue 1 , Pages 69-75 , 20 August 2006

Quality of life assessment in a chemoprevention trial: Fenretinide and oral or transdermal HRT

  • Davide Serrano

      Affiliations

    • Division of Chemoprevention, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 0257489861; fax: +39 0257489809.
    • ,
  • Luigi Mariani

      Affiliations

    • Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
    • National Cancer Institute, Italy
    • ,
  • Serena Mora

      Affiliations

    • Division of Chemoprevention, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy
    • ,
  • Aliana Guerrieri-Gonzaga

      Affiliations

    • Division of Chemoprevention, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy
    • ,
  • Massimiliano Cazzaniga

      Affiliations

    • Division of Chemoprevention, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy
    • ,
  • Cristina Daldoss

      Affiliations

    • Clinics of Obstetrics and Gynecology, University of Brescia, Brescia, Italy
    • ,
  • Francesca Ramazzotto

      Affiliations

    • Clinics of Obstetrics and Gynecology, University of Brescia, Brescia, Italy
    • ,
  • Irene Feroce

      Affiliations

    • Division of Chemoprevention, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy
    • ,
  • Andrea Decensi

      Affiliations

    • Division of Chemoprevention, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy
    • Division of Medical and Preventive Oncology, Galliera Hospital, Genoa, Italy
    • ,
  • Bernardo Bonanni

      Affiliations

    • Division of Chemoprevention, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy

Received 24 June 2005 ,Revised 2 January 2006 ,Accepted 6 January 2006.

Reference 

  1. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet. 2002;360:942–944
  2. Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas. 1996;24:161–175
  3. Decensi A, Bonanni B, Baglietto L, et al. A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers. Clin Cancer Res. 2004;10:4389–4397
  4. Decensi A, Omodei U, Robertson C, et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid–placebo trial in healthy women. Circulation. 2002;106:1224–1228
  5. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003;362:428–432
  6. Perera M, Sattar N, Petrie JR, et al. The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2001;86:1140–1143
  7. Veronesi U, De Palo G, Marubini E, et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst. 1999;91:1847–1856
  8. Decensi A, Torrisi R, Polizzi A, et al. Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface. J Natl Cancer Inst. 1994;86:105–110
  9. Cancer Therapy Evaluation Program. Common toxicity criteria, version 2.0. Bethesda (MD): National Cancer Institute, 30 April, 1999.
  10. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses’ health study. N Engl J Med. 1991;325:756–762
  11. Grodstein F, Stampfer MJ, Falkeborn M, Naessen T, Persson I. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women. Epidemiology. 1999;10:476–480
  12. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801–1811
  13. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333
  14. Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS). Circulation. 2001;103:638–642
  15. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701–1712
  16. The menopausal transition: a different view. Proceedings of an international symposium. Leiden, The Netherlands, 18–19 June 1997. J Psychosom Obstet Gynaecol 1997;18:59–188.
  17. Gelfand MM, Moreau M, Ayotte NJ, Hilditch JR, Wong BA, Lau CY. Clinical assessment and quality of life of postmenopausal women treated with a new intermittent progestogen combination hormone replacement therapy: a placebo-controlled study. Menopause. 2003;10:29–36
  18. Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas. 2003;44:157–163
  19. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005;114:448–454
  20. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet. 1999;353:571–580
  21. Hilditch JR, Lewis J, Ross AH, et al. A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women. Maturitas. 1996;24:177–184
  22. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA. 2002;287:591–597
  23. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003;348:1839–1854

PII: S0378-5122(06)00009-0

doi: 10.1016/j.maturitas.2006.01.005

Maturitas
Volume 55, Issue 1 , Pages 69-75 , 20 August 2006

Article Tools

* Image Usage & Resolution